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Abstract
Background: Talin-1 (TLN-1) and TLN-2 are implicated in many cellular processes, but their roles in hepatocellular
carcinoma (HCC) remain unclear. This study aimed to assess cell cycle distribution, anoikis, invasion and migration in
human HCC MHCC-97 L cells.
Methods: MHCC-97 L cells, which highly express TLN-1, were transduced with TLN-1 shRNA (experimental group)
or scramble shRNA (negative control group); non-transduced MHCC-97 L cells were used as blank controls. TLN-1
and TLN-2 mRNA and protein levels were detected by real-time RT-PCR and western blot, respectively. Then, cell
cycle distribution and anoikis were assessed by flow cytometry. In addition, migration and invasion abilities were
assessed using Transwell and cell scratch assays. Finally, a xenograft nude mouse model was established to further
assess cell tumorigenicity.
Results: Compared with the blank and negative control groups, TLN-1/2 mRNA and protein levels were significantly
reduced in the experiment group. TLN-1/2 knockdown cells showed significantly more cells in the G0/G1 phase
(79.24 %) in comparison with both blank (65.36 %) and negative (62.69 %) control groups; conversely, less cells were
found in G2/M and S phases in the experimental group compared with controls. Moreover, anoikis was enhanced
(P < 0.05), while invasion and migration abilities were reduced (P < 0.05) in TLN-1/2 knockdown cells compared with
controls. TLN-1/2 knockdown inhibited MHCC-97 L cell migration (Percentage of wound healing area: experimental
group: 32.6 ± 0.7 % vs. negative controls: 50.1 ± 0.6 % and blank controls: 53.6 ± 0.6 %, both P < 0.01). Finally, the tumors
obtained with TLN-1/2 knockdown cells were smaller (P < 0.05) compared with controls.
Conclusion: Both TLN-1 and TLN-2 levels correlate with tumorigenicity in human HCC, indicating that these molecules
constitute important molecular targets for the diagnosis and/or treatment of HCC.
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Background
Hepatocellular carcinoma (HCC) is a major health prob-
lem [1]. Recent studies have reported an incidence of
780,000cases/year for HCC, with most individuals diag-
nosed at intermediate or advanced disease stages, where
curative approaches are often not feasible [2]. Although
there is no definitively curative treatment for HCC,
multiple therapeutic and management options exist with
various advantages and disadvantages [3]: the surgical
options include resection, transplantation and ablation;
in addition, radiation therapy and biologic agents such
as Sorafenib have been proposed.
Two talin genes present in vertebrates, namely Talin-1
(TLN-1) and Talin-2 (TLN-2), encode proteins with
74 % sequence identity; TLN-2 is the ancestral gene,
with TLN-1 arising by gene duplication early in the
chordate lineage [4–7]. Despite the high homology be-
tween both talin proteins, differences in the remaining
amino acids may affect protein function [8, 9]. TLN-1 is
primarily expressed in the kidney, liver, spleen, stomach,
lung, and vascular smooth muscle [5, 10–13]. Additionally,
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TLN-2 mRNA expression is most abundant in the heart,
brain, and skeletal muscle [5, 13]. However, other recent
western blotting data and expression studies with a mouse
gene trap line have suggested that TLN-2 may be more
widely expressed [5, 14, 15].
TLN-1 is a cytoskeletal protein of 270 kDa that plays a
pivotal role in regulating the activity of the integrin
family of cell adhesion proteins by coupling them to
F-actin [16, 17]. TLN-1 is also a focal adhesion protein
that binds to multiple adhesion molecules, including
integrins, vinculin, focal adhesion kinase (FAK), and actin.
Moreover, TLN-1 plays an essential role in integrin activa-
tion [18, 19]. Upon activation, integrins increase the func-
tional interaction between cells and the extracellular
matrix (ECM), thus serving as bidirectional transducers of
extracellular and intracellular signals, ultimately regulating
adhesion, proliferation, anoikis, survival, and tumor
progression [18–22]. TLN-1 overexpression has been re-
ported to enhance prostate cancer cell adhesion, migra-
tion, and invasion by activating survival signals and
conferring resistance to anoikis [19]. TLN-1 overexpres-
sion could serve as a diagnostic marker for aggressive phe-
notypes and a potential target for treating oral squamous
cell carcinoma (OSCC) [23]. In addition, kinesin family
member 14 (KIF14) and TLN-1 expression levels predict a
better outcome after cytotoxic chemotherapy, and inhib-
ition of these genes sensitizes triple-negative breast cancer
(TNBC) cells to therapeutic intervention [24]. In a retro-
spective study of banked tissue samples, alpha-actinin and
TLN were found to be completely absent in both endo-
metriosis and endometrioid carcinomas [12, 25]. In HCC
research, Chinese investigators have observed that TLN-1
protein and mRNA levels in HCC tissues are significantly
lower than those in the adjacent non-cancerous tissues
[12]. However, Japanese investigators have reported that
TLN-1 is upregulated in HCC [17], and Egyptian studies
showed that TLN-1 serum levels in HCC patients are
significantly higher [26].
To date, the role and function of TLN-2, as a homolo-
gous gene of TLN-1, in tumors remains unclear. Studies
have demonstrated that the N-terminal TLN-2 FERM
domain binds to β1D-integrin with a higher affinity than
that of TLN-1 [27, 28]. Studies using cultured cells have
clearly established that TLN-2 can compensate for the
loss of TLN-1, supporting cell spreading and focal adhe-
sion (FA) assembly in TLN-1 knockout or knockdown
cells [27, 29, 30]. TLN-1 knockout is embryonic lethal at
gastrulation in mice, whereas TLN-2 knockout mice are
viable and fertile [6, 7, 15].
Previously, we showed that TLN-1 and TLN-2 mRNA
and protein expressions differ significantly among five
human HCC cell lines and the human normal liver LO2
cell line [8]; indeed, TLN-1 and TLN-2 expression levels
might be related to invasion and migration in human
hepatocellular carcinoma (HCC). To further assess the
role of TLN-1 and TLN-2 in HCC, MHCC-97 L cells,
which highly express TLN-1, were selected for gene
knockdown using RNA interference. The effects of
TLN-1/2 silencing on HCC malignancy potential in vivo
were also evaluated.
Methods
The protocols in this study were approved by the Ethics
Committee of Anhui Medical University. Animal testing
was performed in accordance with the international
guiding principles for biomedical research.
Cell culture
Human hepatocellular carcinoma MHCC-97 L cells were
provided by the GanDanYi Experiment Center of Huashan
Hospital affiliated to Fudan University, Shanghai (China),
and cultured in Dulbecco’s modified Eagle’s medium
(DMEM) (Invitrogen, Carlsbad, CA, USA) containing 10 %
fetal bovine serum (FBS) (Invitrogen, Carlsbad, CA, USA)
and antibiotics (penicillin G/streptomycin, 50 μg/ml)
(Sangon Biotech Co., Ltd., Shanghai, China), in a humid
environment at 37 °C with 95 % normal air and 5 % CO2.
Lentivirus-mediated stableTLN-1 knockdown in the
MHCC-97 L cells
A shRNA sequence targeting the TLN-1 gene (GenBank.
No. NM_006289.3) (5’-GCTCGAGATGGCAAGCTTA
AA-3’) and one nonspecific sequence 5’-TTCTCCGAA
CGTGTCACGTTTC-3’ (scramble shRNA) used as the
negative control which did not have any homology with
the target gene were designed and packaged into
Lentivirus and transduced into 293 T cells by Shanghai
GenePharma Co., Ltd (China).
For TLN-1 silencing, 0.5 × 105 MHCC-97 L cells were
plated in 24-well plates in complete culture medium for
24 h. Then, cells were transduced for 72 h with lentivirus-
mediated TLN-1-shRNA and scramble shRNA, res-
pectively (Shanghai GenePharma Co., Ltd, China), under
puromycin selection. Afterwards, the transduced cells were
cultured in DMEM containing 10 % FBS and 3 μg/ml of
puromycin for 12 days (changing the medium every
3 days), and stably transduced cells were obtained. TLN-1
mRNA and protein levels were assessed by real-time
RT-PCR and western blot.
Real-time RT-PCR
Total RNA was extracted using RNeasy Miniprep Kit
(Sangon Biotech Co., Ltd., Shanghai, China) according
to the manufacturer’s instructions, and treated with
Turbo DNase (Ambion, Austin, TX, USA). RNA purity
was determined by measuring absorbance at 260 and
280 nm (A260/280). DNase-treated total RNA (1 μg)
was reverse-transcribed using Superscript III reverse
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transcriptase (Invitrogen, Carlsbad, CA, USA) and 500 ng
of random primers (Promega, Madison, WI, USA). Glycer-
aldehyde 3-phosphate dehydrogenase (GAPDH) was used
as an internal control. The following primer pairs were used
for TLN-1, TLN-2 and GAPDH (http://www.rtprimerd-
b.org/): TLN-1: sense, 5’- TGTAGAGGAGCACGAGA
CGC -3’ and anti-sense, 5’- AAGGAGACAGGGTGG
GAGC -3’; TLN-2: sense, 5’-CTGAGGCTCTTTTCA
CAGCA-3’ and anti-sense, 5’-CTCATCTCATCTGCC
AAGCA-3’; GAPDH: sense: 5’-CATGAGAAGTATGA
CAACAGCCT-3’ and anti-sense, 5’- AGTCCTTCC
ACGATACCAAAGT-3’. Relative gene expression was
quantified by real-time PCR using SYBR Premix Ex Taq™
II (TaKaRa Bio, Dalian, China) on a Lightcycler 480 Real-
Time PCR System (Roche Diagnostics, Meylan, France).
Reactions were carried out with initial denaturation (95 °C
for 3 min) followed by 40 cycles of 95 °C for 12 s, 62 °C
for 30 s, and 72 °C for 30 s. The cycle threshold (Ct) was de-
fined as the number of cycles required for the fluorescent
signal to cross the threshold. First, ΔCt =Ct Gene - Ct GAPDH.
Then, ΔΔCt =ΔCt treated - ΔCt control. Ratios were derived
as proposed elsewhere [31].
Western blotting
Cells were lysed in M-PER Mammalian Protein Extraction
Reagent (Thermo, USA), and equal amounts of pro-
tein were resolved by 6 % sodium dodecyl sulfate-
polyacrylamide gel electrophoresis (SDS-PAGE) and
blotted onto polyvinylidene difluoride (PVDF) membranes
(Millipore). The following specific primary antibodies
were used: anti-TLN-1(ab78291, Abcam, Cambridge, MA,
USA), anti-TLN-2 (ab105458, Abcam, Cambridge, MA,
USA) and anti-β-actin (A5441, SIGMA). Proteins were de-
tected using Pierce ECL Western Blotting Substrate
(Thermo). Band intensities were compared using the
Gel-Pro analyzer software.
Cell cycle evaluation
Cells were fixed in 70 % ethanol overnight at 4 °C. After
PBS washes and incubation in PBS containing 50 μg/mL
propidium iodide (PI) and 200 mg/mL RNase A for
30 min in the dark at room temperature, cells were sub-
sequently subjected to flow cytometry analysis. Cell cycle
progression was analyzed via fluorescence-activated cell
sorting (FACS) on a Partec Flow Max flow cytometer
(Partec, Münster, Germany).
Anoikis evaluation
MHCC-97 L and stably transduced cells were plated in
poly-HEMA–coated 6-well plates. After 12, 48 and 72 h
of culture, cells were harvested, rinsed with PBS, and
apoptosis was evaluated using the Annexin V-PE/7-AAD
apoptosis detection kit (KGA1017, KeyGen Biotech,
Nanjing, China) on BD FACS Calibur flow cytometer.
The percentage of apoptotic cells was derived as the
sum of cell fractions displaying early apoptosis (Annexin
V-positive) and late apoptosis (7-AAD-positive).
Transwell migration and invasion assays
A transwell chamber containing an 8-μm pore poly-
carbonate membrane filter was coated either with
(invasion) or without (migration) matrigel (BD, USA),
and inserted in a 24-well culture plate. 105 cells/well in
0.2 mL serum-free DMEM was added to the upper
chambers of the plates, and DMEM containing 10 %
fetal bovine serum in the lower chambers. The plate was
then incubated at 37 °C in presence of 5 % CO2 for 24 h,
and the filter removed. Cells in the upper chamber that
did not migrate were scraped away with a cotton swap;
trans-membrane cells were fixed in 4 % paraformaldehyde
for 30 min and dyed using crystal violet for 25 min.
Migrating or invading cells were photographed using an
inverted optical microscope (Olympus, Tokyo, Japan).
Quantification of migrating or invading cells was deter-
mined using the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl-
tetrazolium bromide (MTT) method.
Scratch test
Cells were resuspended in complete medium, with dens-
ity adjusted to 1 × 106 cells/ml. Then, 3 ml of cell
suspension was added to each well of a 6-well plate. At
80 % confluence, the medium was removed, and a
scratch with a standard 200 μl pipette tip was made on
the cell layer, equidistant from the dish edges. Wound heal-
ing was quantified using the Image J software (National
Institutes of Health, Bethesda, MD, USA) as the percentage
of wound healing area = [Cell-free area (0 h)- Cell-free area
(72 h)]/Cell-free area (0 h).
Xenograft nude mouse model
Specific-pathogen-free (SPF)-grade adult nude mice (4-6
weeks of age) were housed with pathogen-free fodder,
equipment, and environment. Then, 0.2-ml aliquots of
non-transduced, and TLN-1 shRNA and scramble
shRNA transduced MHCC-97 L cells, respectively
(5 × 107cells/200 μl of PBS) were subcutaneously injected
at the inguinal region of nude mice in a SPF-grade ultra-
clean work station. After 20 days, tumor diameters were
measured every 3 days with Vernier calipers. Tumor
volume (TV) was calculated according to the formula:
TV (mm3) = d2 × D/2, where d and D represent the
shortest and the longest diameters, respectively. The mice
were sacrificed at 29 days after cell implantation, and the
tumors were extracted.
Statistical analysis
Experimental data were analyzed using the Statistical
Package for the Social Sciences (SPSS) 17.0 software (SPSS
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Inc., Chicago, IL, USA) and Microsoft Office Excel 2010
(Microsoft, Redmond, WA, USA). Data are mean ± stand-
ard deviation (SD), and groups were compared using inde-
pendent samples t test and one-way analysis of variance
(ANOVA). P < 0.05 was considered statistically significant.
Results
Establishment of a stable TLN-1 knockdown MHCC-97 L
cell line
As shown in Fig. 1, a stable TLN-1 knockdown MHCC-
97 L cell line was successfully established. According to
fluorescence microscopy, transduction efficiency in
MHCC-97 L cells (the percentage of GFP-positive cells)
was >70 % (Fig. 1a). Furthermore,TLN-1 mRNA and
protein levels in the cells transduced with lentivirus-
mediated TLN-1-shRNA (experimental group) were
markedly reduced compared with the non-transduced
cells (blank controls) and cells transduced with
lentivirus-mediated scramble-shRNA (negative controls)
after 72 h (both P < 0.01), as shown by real-time RT-
PCR (Fig. 1b) and Western blot (Fig. 1c).
Effects of TLN-1 knockdown on TLN-1 and TLN-2 mRNA and
protein expressions in MHCC-97 L cells
The transduced cells were assessed at different time
points for their mRNA and protein expression levels. As
shown in Fig. 2a, TLN-1 mRNA levels were starkly re-
duced after gene silencing compared with the blank and
negative control groups, at 12, 48, and 72 h (all P < 0.01).
Although TLN-2 gene expression was less affected
than that of TLN-1, significant differences were ob-
tained at 48 and 72 h in the experimental group
compared with the blank and negative control groups
(both P < 0.01, Fig. 2b). The same trend was observed
for protein expression, and significantly decreased
TLN-1 and TLN-2 were observed at all time points
(all P < 0.01, Fig 2c and d).
Effects of TLN-1/2 knockdown on cell cycle distribution and
Anoikis in MHCC-97 L cells
As shown in Fig. 3a, TLN-1/2 knockdown cells showed
significantly more cells in the G0/G1 phase (79.24 %) in
comparison with both blank (65.36 %) and negative
Fig. 1 Lentivirus-mediated stable Talin-1 (TLN-1) knockdown in the minimally metastatic HCC MHCC-97 L cells. Blank: non-transduced MHCC-97 L
cells; TLN-1 shRNA: MHCC-97 L cells transduced with lentivirus-mediated TLN-1 shRNA; Scramble shRNA: MHCC-97 L cells transduced with lentivirus-
mediated scramble shRNA. a According to fluorescence microscopy, transduction efficiency in MHCC-97 L cells (the percentage of GFP-positive cells)
was >70 % at 72 h (magnification: ×200). b TLN-1 mRNA expression levels were determined by real-time RT-PCR at 72 h after transduction, with
GAPDH used as an internal control. c TLN-1 protein expression levels were determined by Western blot at 72 h after transduction. β-actin was used as
an internal control. Data are mean ± Standard deviation (SD). **P < 0.01 vs. scramble shRNA
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(62.69 %) control groups; conversely, less cells were
found in G2/M and S phases in the experimental group
compared with controls. Interestingly, anoikis was en-
hanced in the experimental group in comparison with
controls (P < 0.01) (Fig. 3b).
Effects of TLN-1/2 knockdown on migration and invasion in
MHCC-97 L cells
As shown in Fig. 4a and b, respectively, migration and
invasion abilities of MHCC-97 L cells were markedly re-
duced after TLN-1/2 knockdown (all P < 0.01) compared
Fig. 2 Effects of TLN-1 knockdown on TLN-1 and TLN-2 mRNA and protein expression in MHCC-97 L cells. a TLN-1 and (b) TLN-2 mRNA expression
levels were assessed by real-time RT-PCR at 12 h, 48 h and 72 h after transduction. GAPDH was used as an internal control. c TLN-1 and (d) TLN-2
protein amounts were determined by Western blot at 12 h, 48 h and 72 h after transduction. β-actin was used as an internal control.
Data are mean ± SD. **P < 0.01 vs. Blank; ##P < 0.01 vs. scramble shRNA
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with controls. This was confirmed by the wound healing
assay, in which TLN-1/2 knockdown cells showed de-
creased migration distance compared with both control
groups (Percentage of wound healing area: experimental
group: 32.6 ± 0.7 % vs. negative controls: 50.1 ± 0.6 %
and blank controls: 53.6 ± 0.6 %, both P < 0.01) (Fig. 4c).
TLN-1/2 knockdown inhibits tumor growth in vivo
Compared with the blank and negative control groups,
TLN-1 shRNA transduced MHCC-97 L cells yielded
smaller tumor volume in nude mice after subcutaneous
injection, showing weaker cell tumorigenicity. The dif-
ferences were statistically significant at 29 days after cell
inoculation (P < 0.05, Fig. 5a). Representative tumors are
shown in Fig. 5b.
Discussion
The roles of TLN-1 and TLN-2 in HCC are not com-
pletely understood. We previously assessed five human
HCC cell lines and normal liver LO2 cells, and showed
that TLN-1 protein expression levels in MHCC-97 L
cells are highest [8]. In this study we used the lentiviral
interference technology to knockdown TLN-1 expres-
sion in MHCC-97 L cells, generating a stable transduced
cell line. As shown above, TLN-1 knockdown MHCC-
97 L cells showed reduced TLN-1 mRNA and protein
expressions, as well as arrested cell cycle in the G0/G1
phase, enhanced anoikis, decreased invasion and migra-
tion abilities, confirming the involvement of TLN-1 in
HCC progression.
Recent studies have demonstrated the complexity of
the mammalian TLN-2 gene which may have at least
three different protein isoforms expressed in a tissue-
specific manner. Additionally, alternatively spliced tran-
scripts have been described for the vertebrate TLN-2 as
well as the unique ancestral TLN gene, which is closely
related to TLN-2 [6, 17]. Furthermore, TLN-1 and TLN-
2 encode proteins with 74 % sequence identity. Thus we
further investigated the TLN-2 gene and protein expres-
sion by real-time RT-PCR and western blot, respectively,
after TLN-1 knockdown. We unexpectedly discovered
that TLN-2 expression levels were also decreased in
stable TLN-1 knockdown cells. These results indicated
that the selected shRNA sequence targeting the TLN-1
gene was directed towards the consensus sequence of
TLN-2. Thus, the observed changes of cell cycle distri-
bution, anoikis, migration and invasion, and tumor for-
mation inhibition in vivo were likely associated with the
down-regulation of TLN-1 and TLN-2, not just TLN-1.
In this study, TLN-1/2 knockdown resulted in decreased
malignancy potential of MHCC-97 L cells in vitro as
demonstrated with cell cycle arrest at the G0/G1
phase and enhanced anoikis, as well as decreased mi-
gration and invasion capabilities. These corroborate
previous reports that TLN-1 is involved in integrin
activation [7, 8], which leads to the regulation of adhesion,
invasion, proliferation, anoikis, survival, tumor progres-
sion and metastasis [7–11, 32]. Interestingly, our in vivo
mouse xenograft model confirmed the in vitro findings as
smaller tumors were obtained in animals inoculated with
Fig. 3 Effects of TLN-1/2 knockdown on cell cycle distribution and Anoikis in MHCC-97 L cells. a Cell cycle distribution was determined by flow
cytometry using propidium iodide (PI) staining. G0/G1, S and G2/M phase cells were analyzed. b Anoikis was determined by flow cytometry using
Annexin V-PE/7-AAD staining. Early and late apoptotic cells were analyzed. Data are mean ± SD. **P < 0.01 vs. Blank; ##P < 0.01 vs. scramble shRNA
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Fig. 5 TLN-1/2 knockdown inhibits tumor growth in vivo. MHCC-97 L cells (Blank), MHCC-97 L cells transduced with lentivirus-mediated TLN-1/2
shRNA (TLN-1/2 shRNA) or lentivirus-mediated scramble shRNA (Scramble shRNA) (5 × 107 cells/200 μl of PBS) were subcutaneously injected at
the inguinal region of nude mice. a Tumor volume (mm3) was assessed by calipers every 3 days 20 days after cell inoculation. b The mice were
sacrificed at 29 days after cell inoculation, and the tumors were extracted. Data are mean ± SD. *P < 0.05 vs. Blank; #P < 0.05 vs. scramble shRNA
Fig. 4 Effects of TLN-1/2 knockdown on migration and invasion in MHCC-97 L cells. a Migration and (b) invasion abilities of MHCC-97 L cells were
examined by transwell assays. The trans-membrane cells were fixed in 4 % paraformaldehyde and dyed using crystal violet (magnification: ×200).
Quantification of migrating or invading cells was determined using the MTT assay. OD: Optical density. c Migrating ability of MHCC-97 L cells was also
determined by wound healing assay at 0 and 72 h after scratching. The tissue monolayer was imaged under light microscopy (magnification: ×200).
Data are mean ± SD. **P < 0.01 vs. Blank; ##P < 0.01 vs. scramble shRNA
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the TLN-1/2 knockdown MHCC-97 L cells in com-
parison with those of the control (blank and negative)
groups. Interestingly, KIF14 and TLN-1 inhibition was
found to sensitize triple-negative breast cancer
(TNBC) cells to therapeutic intervention [19]. How-
ever, Talin 1 was recently proposed to be a novel player
in the anti-metastatic signaling network of miR-124
[33]. Taken together, these findings suggest that
Talin1/2 might regulate HCC invasion and migration
through complex mechanisms that are not completely
understood.
Although TLN-1 silencing resulted in reduced protein
and mRNA expressions of both TLN-1 and 2, it is likely
that specific targeting of TLN-2 would have different
outcomes. Therefore, we plan in the near future to de-
sign specific shRNA aimed at both TLN-1 and TLN-2 to
further assess the roles of these two proteins in HCC
metastasis and invasion. Alternatively, commercially
available TLN-1- and TLN-2-specific monoclonal anti-
bodies will be used to elucidate individual and combined
effects of TLN-1 and TLN-2 on primary HCC invasion
and migration.
Conclusion
Our results showed that the levels of both TLN-1 and
TLN-2 correlate with tumorigenicity in human HCC,
indicating that these molecules constitute useful molecu-
lar targets in HCC diagnosis and/or treatment.
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